Search: Your Partner for novel, lab-based clinical diagnostic assays and quality controls Specialty Diagnostix is dedicated to the marketing and distribution of novel, laboratory based assays. Joining forces with strong and innovative partners such as Immunalysis Corporation and ARK Diagnostics Inc., Specialty Diagnostix is setting new standards by providing leading edge immunoassays in the area of Drugs of Abuse Screening and Therapeutic Drug Monitoring. Our three keys to success include: Innovation: Development of novel immunoassays to help in the clinical diagnosis of emerging new therapeutic drugs and to challenge the constant output of new recreational drugs on the illicit market. Expertise: Three decades and more of expertise in the field of Drugs of Abuse Testing and Therapeutic Drug Monitoring. Flexibility: Tests for a variety of biological sample matrices – urine, oral fluid and blood Our business is focused on providing products to hospitals, reference laboratories and other institutions and on supporting global business development for our partners. Commercial operations are centered in Passau, Germany for Europe and Sydney, Australia for Asia Pacific. We are currently active in 25 markets, directly serving 15 European and Asia Pacific countries with our experienced commercial teams. European Headquarters Specialty Diagnostix GmbH, Sailerwöhr 16, D-94032 Passau, +49 (0)851 98849300, info@specialtydiagnostix.de Copyright 2021 by Specialty Diagnostix GmbH AGB Imprint Privacy Statement Sitemap

Search: ARK™ Lacosamide Assay ARK™ Lacosamide Assay The ARK™ Lacosamide Assay is a homogeneous enzyme immunoassay for the quantitative determination of lacosamide in human serum on automated clinical chemistry analyzers. The measurements obtained are used in the monitoring of lacosamide levels to help ensure appropriate therapy. Assay Characteristics Excellent precision, even in trough concentrations Fast and efficient routine monitoring for lacosamide Liquid, ready-to-use reagents, calibrators and controls Storage at 2-8°C On-board stability for at least 60 days Does not contain any harmful preservatives, only ≤ 0,09% so Background Lacosamide ((R)-2-(Acetylamino)-N-benzyl-3-methoxy-propionamide) is a third-generation anti-epileptic drug. Under the drug name Vimpat®, lacosamide has been approved, since 2008, for the use in patients above the age of 16 throughout Europe. Together with other anti-epileptic drugs, lacosamide is used for focal epilepsy attacks with or without secondary generalization. The mechanism of action of lacosamide has not yet been fully clarified. It is known that lacosamide selectively increases the slow inactivation of sodium channels, but does not affect their rapid deactivation. Thus, the pathophysiological neuronal over-excitability is normalized without suppressing the usual neuron activity. Download PDF European Headquarters Specialty Diagnostix GmbH, Sailerwöhr 16, D-94032 Passau, +49 (0)851 98849300, info@specialtydiagnostix.de Copyright 2021 by Specialty Diagnostix GmbH AGB Imprint Privacy Statement Sitemap